Karl Peggs is a Professor of Transplant Science and Cancer Immunotherapy, Scientific Director NIHR Blood and Transplant Research Unit for Stem Cells and Immunotherapies, Scientific Co-Chair and Board Member of the British Society of Blood and Marrow Transplantation, and Honorary Consultant in Haematology/Stem Cell Transplantation at UCLH; he is also an Honorary Consultant (non-clinical) at the Royal Marsden Hospital, London.
Karl undertook undergraduate studies at Cambridge University, completing his clinical training at Oxford University Medical School. Following qualification he completed general medical training at Addenbrookes Hospital Cambridge, and specialist haematology training at the John Radcliffe Hospital, Oxford and UCLH, London. During this time he spent 3 years in the research group of Professor Stephen Mackinnon establishing adoptive cellular therapies for viruses. After taking the position of Senior Lecturer at UCL and Head of Adult Stem Cell Transplantation Services, UCLH, he spent 2.5 years at MSKCC, NYC, USA in the laboratory of Professor James Allison studying murine models of regulatory checkpoint blockade, returning in 2007 to establish his research group. His research interests include viral infections, immune reconstitution, adoptive cellular therapies, and regulatory checkpoint-directed immune-therapeutics. He runs a joint Research Laboratory with Dr Sergio Quezada in the UCL Cancer Institute. More recently he has established the clinical translational side of the academic CAR T cell programme at UCLH. He has been a member of the NCRI Lymphoma Clinical Studies Group (2012-2015), NCRI Haematological Oncology Clinical Studies Group (2011-2015), Leukaemia and Lymphoma Research Clinical Trials Committee (2008-2012), Research Pathway Lead for the London Cancer Pathway Board for Haematological Malignancies (2012-2014) and is a member of the BSBMT Clinical Trials Committee (2007-), the Anthony Nolan Medical Advisory Board (2011-), and the NHS Blood and Transplant (NHSBT) Stem Cell and Therapeutic Apheresis Strategy Group (2015-).